相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial
Antonio Omuro et al.
NEURO-ONCOLOGY (2023)
The Impact of Tumor Treating Fields on Glioblastoma Progression Patterns
Martin Glas et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter
Michael Lim et al.
NEURO-ONCOLOGY (2022)
A randomized phase III study of short-course radiotherapy combined with Temozolomide in elderly patients with newly diagnosed glioblastoma; Japan clinical oncology group study JCOG1910 (AgedGlio-PIII)
Yoshiki Arakawa et al.
BMC CANCER (2021)
Clinical practice guidelines for the management of adult diffuse gliomas
Tao Jiang et al.
CANCER LETTERS (2021)
PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma
Antonio Dono et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Tumour treating fields therapy for glioblastoma: current advances and future directions
Ola Rominiyi et al.
BRITISH JOURNAL OF CANCER (2021)
Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma
Lazaros Lazaridis et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2020)
Central Nervous System Cancers Version 3.2020
Louis Burt Nabors et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2020)
CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017
Quinn T. Ostrom et al.
NEURO-ONCOLOGY (2020)
Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial
Ulrich Herrlinger et al.
LANCET (2019)
Correlation of Tumor Treating Fields Dosimetry to Survival Outcomes in Newly Diagnosed Glioblastoma: A Large-Scale Numerical Simulation-Based Analysis of Data from the Phase 3 EF-14 Randomized Trial
Matthew T. Ballo et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2019)
Cost-effectiveness of tumor-treating fields added to maintenance temozolomide in patients with glioblastoma: an updated evaluation using a partitioned survival model
Martin Connock et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?
Alyssa M. Vanderbeek et al.
NEURO-ONCOLOGY (2018)
Phase III randomized trial of autologous cytokine-induced killer cell immunotherapy for newly diagnosed glioblastoma in korea
Doo-Sik Kong et al.
ONCOTARGET (2017)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial
Michael Weller et al.
LANCET ONCOLOGY (2017)
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James R. Perry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma
F. Bernard-Arnoux et al.
NEURO-ONCOLOGY (2016)
A randomised, open label phase III trial with nimotuzumab, an anti-epidermal growth factor receptor monoclonal antibody in the treatment of newly diagnosed adult glioblastoma
Manfred Westphal et al.
EUROPEAN JOURNAL OF CANCER (2015)
Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Mitotic Spindle Disruption by Alternating Electric Fields Leads to Improper Chromosome Segregation and Mitotic Catastrophe in Cancer Cells
Moshe Giladi et al.
SCIENTIFIC REPORTS (2015)
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
Roger Stupp et al.
LANCET ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Net Clinical Benefit Analysis of Radiation Therapy Oncology Group 0525: A Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma
Terri S. Armstrong et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial
Manfred Westphal et al.
LANCET ONCOLOGY (2013)
Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial
Annika Malmstrom et al.
LANCET ONCOLOGY (2012)
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
Wolfgang Wick et al.
LANCET ONCOLOGY (2012)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer
Jennifer S. Temel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials
A. Hilary Calvert et al.
CLINICAL CANCER RESEARCH (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Disruption of cancer cell replication by alternating electric fields
ED Kirson et al.
CANCER RESEARCH (2004)
Placebo effects in oncology
G Chvetzoff et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
分享论文
